Search results
Added:
2 months ago
American College of Cardiology Congress 2026 - Dr Joost Daemen (Thoraxcenter, Erasmus University Medical Center, Rotterdam, NL) joins us to discuss findings from the FAST III trial (NCT04931771; ECRI) a large-scale randomised study comparing fractional flow reserve (FFR) with 3D-quantitative coronary angiography-derived vessel FFR (vFFR) to guide coronary revascularisation.This randomised, open…
View more
Revascularisation in Patients with Cancer
Added:
4 months ago
Review Article
Added:
2 months ago
Source:
Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group…
View more
Added:
1 year ago
EuroPCR 25 - 10-year outcomes from DANAMI-3-PRIMULTI show FFR-guided complete revascularisation in ST-elevation myocardial infarction (STEMI) reduces the risk of future events. We are joined by Dr Thomas Engstrøm (University of Copenhagen, Copenhagen, Denmark) to discuss 10-year outcomes from the multicenter, randomized DANAMI-3-PRIMULTI trial investigating FFR-guided complete…
View more
Added:
9 months ago
Added:
1 year ago
ESC Congress 2024 — Complete revascularisation is safe, reduces ischemic events for up to 4 years, and does not affect long-term mortality.We are joined onsite by Dr Gianluca Campo (University of Ferrara, Ferrara, IT) to discuss the findings from EARTH-STEMI. Previous RCTs have supported the benefit of complete revascularisation in the overall population, however, this has not been confirmed in…
View more
Added:
8 months ago
Learn about revascularisation strategies in cardiogenic shock after acute MI, including culprit-only vs multivessel PCI, from Dr Tara Jones (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Added:
1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study…
View more
Lukla Biasi
Research Area(s) / Expertise:
Job title: Consultant Vascular & Endovascular Surgeon
Author
Added:
2 months ago
Source:
Interventional Cardiology Review Journal
Long-term follow-up from the FAMOUS-NSTEMI trial suggests that a fractional flow reserve-guided strategy for managing patients with non-ST-segment elevation myocardial infarction (NSTEMI) does not reduce adverse cardiovascular outcomes compared to standard angiography-guided care.¹MethodologyFAMOUS-NSTEMI was a prospective, randomised, controlled trial that enrolled 350 patients with NSTEMI…
View more